CL2017002600A1 - Métodos de reparación y regeneración tisular - Google Patents
Métodos de reparación y regeneración tisularInfo
- Publication number
- CL2017002600A1 CL2017002600A1 CL2017002600A CL2017002600A CL2017002600A1 CL 2017002600 A1 CL2017002600 A1 CL 2017002600A1 CL 2017002600 A CL2017002600 A CL 2017002600A CL 2017002600 A CL2017002600 A CL 2017002600A CL 2017002600 A1 CL2017002600 A1 CL 2017002600A1
- Authority
- CL
- Chile
- Prior art keywords
- site
- lesion
- induces
- tissue repair
- cells
- Prior art date
Links
- 230000017423 tissue regeneration Effects 0.000 title abstract 4
- 238000011069 regeneration method Methods 0.000 title 1
- 230000003902 lesion Effects 0.000 abstract 6
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 abstract 2
- 239000010949 copper Substances 0.000 abstract 2
- 229910052802 copper Inorganic materials 0.000 abstract 2
- 230000006378 damage Effects 0.000 abstract 2
- 210000000130 stem cell Anatomy 0.000 abstract 2
- 239000011573 trace mineral Substances 0.000 abstract 2
- 235000013619 trace mineral Nutrition 0.000 abstract 2
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000004069 differentiation Effects 0.000 abstract 1
- 230000007646 directional migration Effects 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 230000007246 mechanism Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000005012 migration Effects 0.000 abstract 1
- 238000013508 migration Methods 0.000 abstract 1
- 210000001719 neurosecretory cell Anatomy 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
- 230000000451 tissue damage Effects 0.000 abstract 1
- 231100000827 tissue damage Toxicity 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5052—Proteins, e.g. albumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Prostheses (AREA)
Abstract
<p>La divulgación proporciona el suministro local de un elemento traza en un sitio de daño tisular, que desencadena el mecanismo de reparación tisular inherente del cuerpo. El suministro local de cobre en el sitio de la lesión induce la migración (es decir, la migración dirigida) de células madre hacia el sitio de la lesión, desencadena la diferenciación de células madre en el sitio de la lesión, induce la regeneración tisular en el sitio de la lesión, induce moléculas de señalización que desencadenan la regeneración tisular, revierte el daño en el sitio de la lesión y/o reconstruye el microambiente de células neurofibrilares y células neurosecretoras en el sitio de la lesión. En otro aspecto, se desvela el suministro de un elemento traza (por ejemplo, cobre) directamente en el sitio de la lesión y los métodos asociados.</p>
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2015/077136 WO2016168993A1 (en) | 2015-04-22 | 2015-04-22 | Methods of tissue repair and regeneration |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2017002600A1 true CL2017002600A1 (es) | 2018-03-23 |
Family
ID=57142823
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2017002600A CL2017002600A1 (es) | 2015-04-22 | 2017-10-13 | Métodos de reparación y regeneración tisular |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US11077138B2 (es) |
| EP (1) | EP3285782B1 (es) |
| JP (2) | JP6895388B2 (es) |
| KR (2) | KR20170137919A (es) |
| CN (1) | CN107921062B (es) |
| AU (1) | AU2016250971B2 (es) |
| BR (1) | BR112017022355A2 (es) |
| CA (1) | CA2982840C (es) |
| CL (1) | CL2017002600A1 (es) |
| CO (1) | CO2017010382A2 (es) |
| DK (1) | DK3285782T3 (es) |
| EA (1) | EA038598B1 (es) |
| EC (1) | ECSP17068922A (es) |
| ES (1) | ES2898655T3 (es) |
| HK (1) | HK1251181A1 (es) |
| HU (1) | HUE056650T2 (es) |
| IL (1) | IL255116B (es) |
| MX (1) | MX2017013122A (es) |
| MY (1) | MY189322A (es) |
| NZ (1) | NZ736516A (es) |
| PE (1) | PE20180240A1 (es) |
| SG (1) | SG11201708431QA (es) |
| TW (1) | TWI702956B (es) |
| UA (1) | UA124332C2 (es) |
| WO (2) | WO2016168993A1 (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016168993A1 (en) | 2015-04-22 | 2016-10-27 | Innolife Co., Ltd. | Methods of tissue repair and regeneration |
| WO2017049529A1 (en) | 2015-09-24 | 2017-03-30 | Innolife Co., Ltd. | A pharmaceutical composition comprising a copper chelating tetramine and the use thereof |
| CN106754662B (zh) * | 2016-11-21 | 2019-11-12 | 中国人民解放军军事医学科学院基础医学研究所 | 心肌细胞的制备方法 |
| TWI615127B (zh) * | 2017-01-17 | 2018-02-21 | 正崴精密工業股份有限公司 | 計算血壓的方法及其裝置 |
| WO2018217710A1 (en) * | 2017-05-22 | 2018-11-29 | The Regents Of The University Of California | Micro/nanobubble solutions for tissue preservation and generation thereof |
| TWI634528B (zh) * | 2017-08-29 | 2018-09-01 | 國立臺北商業大學 | 用於評估認知能力的電腦程式產品 |
| TWI635469B (zh) * | 2017-08-29 | 2018-09-11 | 國立臺北商業大學 | 用於反應力訓練的電腦程式產品 |
| KR102121417B1 (ko) * | 2018-10-08 | 2020-06-10 | 가천대학교 산학협력단 | Stat3 활성화제를 이용한 골격근세포 분화 유도용 조성물 및 이를 이용한 골격근세포 분화 유도 방법 |
| US12285182B2 (en) | 2018-10-10 | 2025-04-29 | Innova Vascular, Inc. | Devices and methods for removing an embolus |
| CN109513037B (zh) * | 2018-11-14 | 2021-09-17 | 华中科技大学同济医学院附属协和医院 | 一种负载介孔生物玻璃的小肠粘膜下层创面敷料 |
| WO2020172113A1 (en) * | 2019-02-18 | 2020-08-27 | Lankenau Institute For Medical Research | Scar reducing wound closure materials |
| CN110288581B (zh) * | 2019-06-26 | 2022-11-04 | 电子科技大学 | 一种基于保持形状凸性水平集模型的分割方法 |
| WO2020261133A1 (en) * | 2019-06-27 | 2020-12-30 | Friedrich Miescher Institute For Biomedical Research | Promoting tissue regeneration |
| CN111297895A (zh) * | 2020-02-20 | 2020-06-19 | 成都因诺生物医药科技有限公司 | 用于治疗动脉粥样硬化的组合物的制药用途 |
| JP2024509661A (ja) * | 2020-12-22 | 2024-03-05 | フルイデックス メディカル テクノロジー，インコーポレイテッド | 一過性造影剤入りの、その場で固化する注入可能な組成物、並びにそれらの製造及び使用方法 |
| WO2023039353A2 (en) * | 2021-09-08 | 2023-03-16 | The Board Of Trustees Of The University Of Illinois | Real-time super-resolution ultrasound microvessel imaging and velocimetry |
| CN114010163B (zh) * | 2021-12-02 | 2023-12-19 | 中国中医科学院医学实验中心 | 基于光学成像的表皮细胞迁移定位系统及方法 |
| CN114469897B (zh) * | 2022-01-12 | 2023-02-28 | 上海市胸科医院 | 靶向治疗心肌梗死的锂皂石复合递送材料及其制备与应用 |
| CN115177786A (zh) * | 2022-07-14 | 2022-10-14 | 山东大学 | 一种原位负载蒙脱土/纳米羟基磷灰石的壳聚糖复合支架材料及其制备方法 |
| KR20240164682A (ko) * | 2023-05-12 | 2024-11-20 | 국립해양생물자원관 | 다중구리 산화효소 펩타이드 및 이로부터 유래된 펩타이드를 포함하는 상처 치유 또는 피부 재생용 조성물 |
| CN117547554B (zh) * | 2024-01-12 | 2024-05-14 | 山东康根源生物集团有限公司 | 一种间充质干细胞修复制剂及其制备方法 |
| CN118879625A (zh) * | 2024-07-24 | 2024-11-01 | 南方医科大学珠江医院 | 一种硫化铜工程化干细胞外泌体的制备方法及其应用 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5580575A (en) | 1989-12-22 | 1996-12-03 | Imarx Pharmaceutical Corp. | Therapeutic drug delivery systems |
| JPH03297475A (ja) * | 1990-04-16 | 1991-12-27 | Ken Ishihara | 共振音波により薬物の放出を制御する方法 |
| US5558082A (en) | 1995-01-09 | 1996-09-24 | Spencer; Robert F. | Method of intubating a patient and introducer for use with such method |
| DE69724599T2 (de) | 1996-03-12 | 2004-08-05 | The Board Of Regents Of The University Of Nebraska, Lincoln | Zusammensetzung zur zielortspezifischen verabreichung eines medikamentes und verfahren zur anwendung |
| US6896659B2 (en) | 1998-02-06 | 2005-05-24 | Point Biomedical Corporation | Method for ultrasound triggered drug delivery using hollow microbubbles with controlled fragility |
| GB9826658D0 (en) | 1998-12-03 | 1999-01-27 | Univ London | Tissue repair |
| HUP0400181A2 (en) * | 2001-06-12 | 2007-08-28 | Vivoxid Oy | Porous sponge-like cellulosic material for treatment of injuries |
| CN1688301A (zh) | 2002-08-20 | 2005-10-26 | 普罗特米克斯公司 | 药物剂型及相关的治疗用途 |
| WO2004017956A1 (en) | 2002-08-20 | 2004-03-04 | Protemix Corporation Limited | Dosage forms and related therapies |
| KR101528918B1 (ko) | 2004-11-07 | 2015-06-15 | 쿠프론 인코포레이티드 | 상처, 화상 및 다른 피부 질환을 치료하기 위한 구리 함유물질 |
| US20070048387A1 (en) * | 2005-09-01 | 2007-03-01 | Edwards Jeffrey D | Tissue disruption treatment and composition for use thereof |
| WO2008057443A2 (en) | 2006-11-03 | 2008-05-15 | Multiple Sclerosis Research Center Of New York | Bone marrow-derived mesenchymal stem cells as a source of neural progenitors |
| US8481066B2 (en) | 2009-07-16 | 2013-07-09 | The Curators Of The University Of Missouri | Scaffold for tissue regeneration in mammals |
| US8287896B2 (en) * | 2010-01-06 | 2012-10-16 | The Curators Of The University Of Missouri | Scaffolds with trace element for tissue regeneration in mammals |
| EP2453844B1 (en) * | 2009-07-16 | 2020-09-02 | The Curators Of The University Of Missouri | Scaffolds with trace element for tissue regeneration in mammals |
| CN102302507B (zh) * | 2010-07-12 | 2014-02-05 | 四川大学华西医院 | 定向控释微量元素的药物组合物及制备方法和应用 |
| CN101926821B (zh) | 2010-07-12 | 2012-01-25 | 四川大学华西医院 | 一种靶向释放微量元素的药物组合物及制备方法和应用 |
| US20150072396A1 (en) | 2011-03-04 | 2015-03-12 | Life Technologies Corporation | Compounds and Methods for Conjugation of Biomolecules |
| JP5598864B2 (ja) | 2011-12-05 | 2014-10-01 | 北海道公立大学法人 札幌医科大学 | 細胞増殖方法ならびに組織の修復および再生のための医薬 |
| CN103467578B (zh) * | 2012-06-08 | 2015-07-08 | 四川大学华西医院 | 一种短肽、载铜纳米生物材料及在制备治疗脑梗死的药物中的应用 |
| WO2014027474A1 (ja) * | 2012-08-17 | 2014-02-20 | 株式会社Ｃｌｉｏ | 心筋梗塞の修復再生を誘導する多能性幹細胞 |
| WO2014035465A1 (en) | 2012-08-28 | 2014-03-06 | Original Biomedicals Co., Ltd. | The controlled release method for a pharmaceutical composition composed of chelating complex micelles |
| WO2014132262A1 (en) | 2013-02-28 | 2014-09-04 | Ramot At Tel-Aviv University Ltd. | Peptide-based hydrogel particles and uses thereof |
| CN105753719B (zh) | 2014-12-17 | 2019-06-21 | 四川科瑞德凯华制药有限公司 | 一种盐酸曲恩汀化合物 |
| WO2016168993A1 (en) | 2015-04-22 | 2016-10-27 | Innolife Co., Ltd. | Methods of tissue repair and regeneration |
| WO2017049529A1 (en) | 2015-09-24 | 2017-03-30 | Innolife Co., Ltd. | A pharmaceutical composition comprising a copper chelating tetramine and the use thereof |
-
2015
- 2015-04-22 WO PCT/CN2015/077136 patent/WO2016168993A1/en not_active Ceased
-
2016
- 2016-04-08 KR KR1020177033507A patent/KR20170137919A/ko not_active Ceased
- 2016-04-08 CA CA2982840A patent/CA2982840C/en active Active
- 2016-04-08 PE PE2017002201A patent/PE20180240A1/es unknown
- 2016-04-08 NZ NZ736516A patent/NZ736516A/en unknown
- 2016-04-08 JP JP2017555688A patent/JP6895388B2/ja active Active
- 2016-04-08 HU HUE16782563A patent/HUE056650T2/hu unknown
- 2016-04-08 DK DK16782563.7T patent/DK3285782T3/da active
- 2016-04-08 UA UAA201711249A patent/UA124332C2/uk unknown
- 2016-04-08 WO PCT/CN2016/078873 patent/WO2016169416A1/en not_active Ceased
- 2016-04-08 AU AU2016250971A patent/AU2016250971B2/en active Active
- 2016-04-08 MY MYPI2017703903A patent/MY189322A/en unknown
- 2016-04-08 EA EA201792307A patent/EA038598B1/ru unknown
- 2016-04-08 ES ES16782563T patent/ES2898655T3/es active Active
- 2016-04-08 HK HK18110758.1A patent/HK1251181A1/zh unknown
- 2016-04-08 MX MX2017013122A patent/MX2017013122A/es unknown
- 2016-04-08 BR BR112017022355A patent/BR112017022355A2/pt not_active Application Discontinuation
- 2016-04-08 KR KR1020197037851A patent/KR102347010B1/ko active Active
- 2016-04-08 CN CN201680029765.5A patent/CN107921062B/zh active Active
- 2016-04-08 EP EP16782563.7A patent/EP3285782B1/en active Active
- 2016-04-08 US US15/568,386 patent/US11077138B2/en active Active
- 2016-04-08 SG SG11201708431QA patent/SG11201708431QA/en unknown
- 2016-04-21 TW TW105112419A patent/TWI702956B/zh active
-
2017
- 2017-10-11 CO CONC2017/0010382A patent/CO2017010382A2/es unknown
- 2017-10-13 CL CL2017002600A patent/CL2017002600A1/es unknown
- 2017-10-17 EC ECIEPI201768922A patent/ECSP17068922A/es unknown
- 2017-10-18 IL IL255116A patent/IL255116B/en active IP Right Grant
-
2020
- 2020-06-04 JP JP2020097590A patent/JP2020143158A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2017002600A1 (es) | Métodos de reparación y regeneración tisular | |
| CR20190063A (es) | 3-metil pirazinas 2,5-disustituídas y 3-metil pirazinas 2,5,6-trisustituídas como inhibidores alostéricos de shp2 | |
| CL2017002066A1 (es) | Proteasas de cisteína | |
| MX373132B (es) | Suplemento a base de teacrina y método de uso del mismo. | |
| CL2015002443A1 (es) | Péptidos y composiciones para el tratamiento del daño articular | |
| UY37124A (es) | Nuevos compuestos de 6,7-dihidro-5h-benzo[7]anuleno sustituidos, procesos para su preparación y usos terapéuticos de los mismos | |
| MX2017014375A (es) | Moduladores del ccr2. | |
| BR112018007437A2 (pt) | reticulação de colágeno induzida por laser em tecido | |
| AR099101A1 (es) | Dispositivo de fijación externo para tratar fracturas óseas | |
| MX2020004837A (es) | Inhibidores de la vía de adenosina para el tratamiento del cáncer. | |
| CL2015003357A1 (es) | Derivados de nucleósidos 4'-fluoro-2'-metil sustituidos | |
| UY32551A (es) | Compuestos peptidomiméticos de sulfamida y usos antivirales de los mismos | |
| AR096672A1 (es) | Compuestos de tipo estrobilurina para combatir hongos fitopatogénicos | |
| UY32554A (es) | Compuestos peptidomiméticos de sulfonamida y usos antivirales de los mismos | |
| MX2017004148A (es) | Composiciones, kits y metodos para inducir citorresistencia adquirida usando inductores de proteinas de estres. | |
| MX383670B (es) | Nuevos marcadores de la diferenciación de th17 para el acné y usos de los mismos. | |
| AR106364A1 (es) | Derivados de insulina y sus usos médicos | |
| MX2017001352A (es) | Derivados de pirrolidinona como inhibidores de metionina aminopeptidasa 2 (metap-2). | |
| CL2016000597A1 (es) | Derivados de desoxino jirimicina y sus métodos de uso. | |
| CL2021000329A1 (es) | Compuestos útiles en terapia del vih | |
| CL2017001025A1 (es) | Compuestos para usarse en el tratamiento antihelmíntico | |
| BR112015024860A2 (pt) | vacinas que compreendem polipeptídeos de leishmania para o tratamento e diagnóstico de leishmaniose | |
| CL2017001579A1 (es) | Copolímeros de polidialilamina reticulados para el tratamiento de la diabetes de tipo 2 | |
| CL2019000027A1 (es) | Regímenes de dosificación de antagonistas de la lingo-1 y usos para el tratamiento de los trastornos desmielinizantes. | |
| BR112015029145A2 (pt) | Usos de um domínio extracelular (ecd) de receptor de fator de crescimento de fibroblastos 1 (fgfr1) e métodos de identificação de pacientes |